# SAFETY DATA SHEET



# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation

ZOVIRAX OPHTHALMIC OINTMENT

of the mixture

Registration number

ZOVIRAX OPHTHALMIC OINTMENT 3% \* ZOVIRAX ACU ZIEDE \* ZOVIRAX AUGENSALBE \* **Synonyms** 

ZOVIRAX MASC DO OCZU \* ZOVIRAX OCNA MAST \* ZOVIRAX OGONSALVA \* ZOVIRAX ONGUENT OPHTALMIQUE \* ZOVIRAX OOGZALF \* ZOVIRAX OYESALVE \* ZOVIRAX POMADA OFTALMICA \* ZOVIRAX POMATA OFTALMICO \* ZOVIRAX POMMADE OPHTHALMIQUE \* ZOVIRAX UNGUENTO OFTALMICO \* ACYVIR EYE OINTMENT \* ZOVIR EYE OINTMENT \*

ACYCLOVIR, FORMULATED PRODUCT

23-October-2014 Issue date

Version number 10

**Revision date** 23-October-2014

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product.

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Uses advised against No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK 980 Great West Road

Brentford, Middlesex TW8 9GS UK

UK General Information (normal business hours): +44-20-8047-5000

Email Address: msds@gsk.com Website: www.gsk.com

1.4. Emergency telephone

number

TRANSPORT EMERGENCIES::

UK In-country toll call: +(44)-870-8200418 International toll call: +1 703 527 3887

available 24 hrs/7 days; multi-language response

### **SECTION 2: Hazards identification**

#### 2.1. Classification of the substance or mixture

# Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

# Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

#### 2.2. Label elements

# Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.3. Other hazards This product will support combustion at elevated temperatures.

Caution - Pharmaceutical agent. See section 11 for additional information on health hazards.

### SECTION 3: Composition/information on ingredients

### 3.2. Mixtures

Material name: ZOVIRAX OPHTHALMIC OINTMENT SDS MALTA

#### **General information**

Chemical name		%	CAS-No. / EC No.	REACH Registration No.	INDEX No.	Notes
PHARMACEUTICAL GRADE PETROLATUM		97	8009-03-8 232-373-2	-	649-254-00-X	
Classification:	DSD: -					N
	CLP: -					N
ACYCLOVIR		3	59277-89-3 261-685-1	-	-	
Classification:	DSD: -					
	CLP: -					

# List of abbreviations and symbols that may be used above

CLP: Regulation No. 1272/2008. DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance. PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

#### **SECTION 4: First aid measures**

**General information** In the case of accident or if you feel unwell, seek medical advice immediately (show the label

where possible). Ensure that medical personnel are aware of the material(s) involved, and take

precautions to protect themselves.

4.1. Description of first aid measures

Inhalation Move to fresh air. If breathing is difficult, trained personnel should give oxygen. Call a physician if

symptoms develop or persist. Under normal conditions of intended use, this material is not

expected to be an inhalation hazard.

Skin contact Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse.

Get medical attention if symptoms occur.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

Ingestion If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large

amount does occur, call a poison control centre immediately. Do not induce vomiting without

advice from poison control center.

4.2. Most important symptoms and effects, both acute and

delayed

4.3. Indication of any immediate medical attention and special treatment needed None known. Direct contact with eyes may cause temporary irritation.

No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

# **SECTION 5: Firefighting measures**

General fire hazards This product will support combustion at elevated temperatures.

5.1. Extinguishing media

Suitable extinguishing

media

Foam. Dry chemical powder. Carbon dioxide (CO2).

Unsuitable extinguishing

media

Water.

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting

procedures

Move containers from fire area if you can do so without risk.

Specific methods Use standard firefighting procedures and consider the hazards of other involved materials.

Material name: ZOVIRAX OPHTHALMIC OINTMENT

SDS MALTA

#### **SECTION 6: Accidental release measures**

### 6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Wear appropriate protective equipment and clothing during clean-up. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8.

For emergency responders

Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the

6.2. Environmental precautions

Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Avoid discharge into drains, water courses or onto the ground. Inform appropriate managerial or supervisory personnel of all environmental releases.

6.3. Methods and material for containment and cleaning up Large Spills: Stop the flow of material, if this is without risk. Use water spray to reduce vapours or divert vapour cloud drift. Dike the spilled material, where this is possible. Cover with plastic sheet to prevent spreading. Absorb in vermiculite, dry sand or earth and place into containers. Prevent entry into waterways, sewer, basements or confined areas. Following product recovery, flush area

Small Spills: Wipe up with absorbent material (e.g. cloth, fleece). Clean surface thoroughly to remove residual contamination.

Never return spills to original containers for re-use.

6.4. Reference to other sections

For personal protection, see section 8. For waste disposal, see section 13 of the SDS.

### **SECTION 7: Handling and storage**

7.1. Precautions for safe handling

No special control measures required for the normal handling of this product. Avoid prolonged exposure. Provide adequate ventilation. Avoid release to the environment.

7.2. Conditions for safe storage, including any incompatibilities

Keep away from heat, sparks and open flame. Store in original tightly closed container. Store away

from incompatible materials (see Section 10 of the SDS).

7.3. Specific end use(s) Medicinal Product.

# **SECTION 8: Exposure controls/personal protection**

# 8.1. Control parameters

#### Occupational exposure limits

**GSK** 

Components	Туре	Value	
ACYCLOVIR (CAS 59277-89-3)	8 HR TWA	5000 mcg/m3	
,	OHC	1	

**Biological limit values** 

No biological exposure limits noted for the ingredient(s).

Recommended monitoring procedures

Follow standard monitoring procedures.

Derived no-effect level (DNEL)

Not available. Not available.

Predicted no effect concentrations (PNECs)

Exposure guidelines

8.2. Exposure controls

General ventilation normally adequate.

Appropriate engineering controls

### Individual protection measures, such as personal protective equipment

**General information** Personal protection equipment should be chosen according to the CEN standards and in

discussion with the supplier of the personal protective equipment. Follow all local regulations if

personal protective equipment (PPE) is used in the workplace.

If contact is likely, safety glasses with side shields are recommended. (e.g. EN 166). Not normally Eye/face protection

needed.

Skin protection

- Hand protection For prolonged or repeated skin contact use suitable protective gloves. Select suitable chemical

resistant protective gloves (EN 374) with a protective index 6 (>480min permeation time).

- Other Wear suitable protective clothing as protection against splashing or contamination. (EN 14605 for

splashes, EN ISO 13982 for dust). Not normally needed.

Material name: ZOVIRAX OPHTHALMIC OINTMENT

SDS MALTA

Respiratory protection When workers are facing concentrations above the exposure limit they must use appropriate

certified respirators. No personal respiratory protective equipment normally required.

**Thermal hazards** Wear appropriate thermal protective clothing, when necessary.

Hygiene measures Always observe good personal hygiene measures, such as washing after handling the material

and before eating, drinking, and/or smoking. Routinely wash work clothing and protective

equipment to remove contaminants.

**Environmental exposure controls** 

Hazard guidance and control recommendations

Inform appropriate managerial or supervisory personnel of all environmental releases.

#### **SECTION 9: Physical and chemical properties**

#### 9.1. Information on basic physical and chemical properties

**Appearance** 

Physical state
Form
Colour
Odour
Odour
Odour threshold
PH
Not available.

range

Flash point 182 - 221 °C (359,6 - 429,8 °F) Closed cup (Estimation based on components).

Evaporation rate Not available.
Flammability (solid, gas) Not available.
Upper/lower flammability or explosive limits

Flammability limit - lower

(%)

Not available.

Flammability limit - upper

(%)

Not available.

Vapour pressureNot available.Vapour densityNot available.Relative densityNot available.

Solubility(ies)

Solubility (water) Not available.
Solubility (other) Not available.
Partition coefficient Not available.

(n-octanol/water)

Auto-ignition temperature

Decomposition temperature

Viscosity

Explosive properties

Oxidizing properties

Not available.

Not available.

Not available.

Not available.

Not available.

**9.2. Other information** No relevant additional information available.

### **SECTION 10: Stability and reactivity**

**10.1. Reactivity** The product is stable and non-reactive under normal conditions of use, storage and transport.

**10.2. Chemical stability** Material is stable under normal conditions.

10.3. Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

**10.4. Conditions to avoid** Keep away from heat, sparks and open flame. Contact with incompatible materials.

10.5. Incompatible materials Strong oxidising agents.

ottoring attaches of the control of

10.6. Hazardous decomposition products

Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition.

### **SECTION 11: Toxicological information**

**General information** Occupational exposure to the substance or mixture may cause adverse effects.

### Information on likely routes of exposure

Inhalation Under normal conditions of intended use, this material is not expected to be an inhalation hazard.

Skin contact Health injuries are not known or expected under normal use. Eye contact Health injuries are not known or expected under normal use.

Health injuries are not known or expected under normal use. Expected to be a low ingestion Ingestion

hazard. However, ingestion is not likely to be a primary route of occupational exposure.

None known. Direct contact with eyes may cause temporary irritation. **Symptoms** 

### 11.1. Information on toxicological effects

Health injuries are not known or expected under normal use. **Acute toxicity** 

Components	Species	Test resu	lts
------------	---------	-----------	-----

ACYCLOVIR (CAS 59277-89-3)

**Acute** Inhalation

LC50 Rat > 15,1 mg/l, 4 hours

Oral

LD50 Rat > 20 g/kg

PHARMACEUTICAL GRADE PETROLATUM (CAS 8009-03-8)

Acute

Oral

LD50 Rat > 15 g/kg

Chronic

Oral

**NOAEL** Rat >= 3000 mg/kg, 2 years

Skin corrosion/irritation Health injuries are not known or expected under normal use.

**Irritation Corrosion - Skin** 

**ACYCLOVIR** Acute dermal irritation, Tested at 5% in a cream; Irritation

Index 0,02 Result: negative Species: Rabbit

Serious eye damage/eye irritation

Direct contact with eyes may cause temporary irritation. Health injuries are not known or expected

under normal use.

Eve

**ACYCLOVIR** Acute ocular irritation Result: negative

Species: Rabbit

Not available. Respiratory sensitisation

Skin sensitisation Health injuries are not known or expected under normal use.

Sensitisation

**ACYCLOVIR** Method not specified

> Result: negative Species: Guinea pig

Germ cell mutagenicity Health injuries are not known or expected under normal use.

Mutagenicity

**ACYCLOVIR** Ames Assay

Result: negative

C3H/T10 1/2 Cell Transformation Assay

Result: negative

Chromosomal Aberration Assay In Vitro, Positive response only with levels much above equivalent of human therapeutic

dose

Result: positive Species: Hamster

Chromosomal Aberration Assay In Vitro, human lymphocytes

Result: Equivocal

Cytogenetic Analysis In Vivo, bone marrow

Result: negative Species: Mouse

Mouse lymphoma cell (L5178Y TK) Assay

Result: positive

Material name: ZOVIRAX OPHTHALMIC OINTMENT

SDS MALTA 127132 Version #: 10 Revision date: 23-October-2014 Issue date: 23-October-2014

<sup>\*</sup> Estimates for product may be based on additional component data not shown.

Carcinogenicity

**ACYCLOVIR** 2 year bioassay

Result: negative Species: Mouse 2 year bioassay Result: negative Species: Rat

PHARMACEUTICAL GRADE PETROLATUM >= 3000 mg/kg/day 2 year bioassay, oral administration

> Result: NOAEL Species: Rat Dermal application Result: negative Species: Mouse

IARC Monographs. Overall Evaluation of Carcinogenicity

ACYCLOVIR (CAS 59277-89-3) 3 Not classifiable as to carcinogenicity to humans.

Reproductive toxicity Health injuries are not known or expected under normal use.

Fertility effects - Males and females

**ACYCLOVIR** 0, Subcutaneous injection

> Result: NOAEL = 25 mg/kg/day; LOAEL = 50 mg/kg/day (decreased implantation efficiency, no effect on litter size)

Species: Rat

Reproductivity

**ACYCLOVIR** Embryo-foetal development - Oral, sub-cutaneous

administration

Result: NOAEL = 50 mg/kg/day; no adverse foetal effects

Species: Rabbit

Embryo-foetal development - Oral, sub-cutaneous

administration

Result: NOAEL = 50 mg/kg/day; no adverse foetal effects

Species: Rat

Specific target organ toxicity -

single exposure

None known. None known.

Specific target organ toxicity -

repeated exposure

Not available.

**Aspiration hazard** Mixture versus substance

Microtox

Chronic

Crustacea

No information available.

information

Other information Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause

adverse effects.

### **SECTION 12: Ecological information**

12.1. Toxicity Not expected to be harmful to aquatic organisms.

Components **Species Test results** ACYCLOVIR (CAS 59277-89-3) Aquatic Acute IC50 Activated Sludge Residential sludge > 100 mg/l, 3 hours OECD 209 Respiration

EC50 Algae Green algae (Selenastrum > 99 mg/l, 96 hours Static test, OECD capricornutum) Crustacea EC50 Water flea (Daphnia magna) > 93 mg/l, 48 hours Static test, OECD

Fish EC50 Fathead minnow (Juvenile Pimephales > 95 mg/l, 96 hours Static renewal test,

**OECD 203** promelas)

Aspergillus flavus > 993 mg/l, 5 days Azotobacter chroococcum > 993 mg/l, 5 days Chaetomium globosum > 993 mg/l, 5 days Nostoc sp. > 993 mg/l, 5 days

Pseudomonas fluorescens

Water flea (Ceriodaphnia dubia) > 10 mg/l, 7 days 7 day static renewal,

> 993 mg/l, 5 days

EPA 1002

127132 Version #: 10 Revision date: 23-October-2014 Issue date: 23-October-2014

Material name: ZOVIRAX OPHTHALMIC OINTMENT

MIC

LOEC

Components Species Test results

NOEC Water flea (Ceriodaphnia dubia)

\* Estimates for product may be based on additional component data not shown.

12.2. Persistence and

No data is available on the degradability of this product.

10 mg/l, 7 days

degradability

**Photolysis** 

Half-life (Photolysis-aqueous)

ACYCLOVIR 3,55 Hours Measured, pH 7 Buffer Solution

**Hydrolysis** 

Half-life (Hydrolysis-neutral)

ACYCLOVIR > 1 years Measured

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

ACYCLOVIR 50 %, < 1 day Modified Zahn-Wellens, Activated sludge

Percent degradation (Aerobic biodegradation-ready)

ACYCLOVIR 0,7 %, 28 days Sturm test

**12.3. Bioaccumulative potential** No data available for this product.

Partition coefficient n-octanol/water (log Kow)

ACYCLOVIR -1,2

**12.4. Mobility in soil** No data available.

Adsorption

Sludge/biomass distribution coefficient - log Kd

ACYCLOVIR 2,33 - 2,37 Estimated

Soil/sediment sorption - log Koc

ACYCLOVIR 2,6 - 2,64 Measured

Mobility in general Not available.

12.5. Results of PBT Not available.

and vPvB assessment

12.6. Other adverse effects Not available.

# **SECTION 13: Disposal considerations**

#### 13.1. Waste treatment methods

**Residual waste** Dispose of in accordance with local regulations. Empty containers or liners may retain some

product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions). Avoid discharge into water courses or onto the ground.

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

**EU waste code**The Waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

**Disposal methods/information** Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not

discharge into drains, water courses or onto the ground. Dispose in accordance with all applicable

regulations.

**Special precautions**Dispose in accordance with all applicable regulations.

# **SECTION 14: Transport information**

#### **ADR**

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine

according to Annex II of environment. These materials may not be transported in bulk.

MARPOL73/78 and the IBC Code

# **SECTION 15: Regulatory information**

# 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### **EU** regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed.

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(10) Candidate List as currently published by ECHA

Not listed.

#### **Authorisations**

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended Not listed.

#### Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended PHARMACEUTICAL GRADE PETROLATUM (CAS 8009-03-8)

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

PHARMACEUTICAL GRADE PETROLATUM (CAS 8009-03-8)

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

PHARMACEUTICAL GRADE PETROLATUM (CAS 8009-03-8)

## Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work PHARMACEUTICAL GRADE PETROLATUM (CAS 8009-03-8)

Directive 94/33/EC on the protection of young people at work

PHARMACEUTICAL GRADE PETROLATUM (CAS 8009-03-8)

Other regulations The product is classified and labelled in accordance with EC directives or respective national laws.

This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.

National regulations Follow national regulation for work with chemical agents.

15.2. Chemical safety No Chemical Safety Assessment has been carried out.

assessment

#### **SECTION 16: Other information**

**List of abbreviations** Not available.

**References** GSK Hazard Determination

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation

methods and test data, if available.

Full text of any statements or R-phrases and H-statements under Sections 2 to 15 None.

**Revision information** Product and Company Identification: Product and Company Identification

Composition / Information on Ingredients: Ingredients

Physical & Chemical Properties:

Transport Information: Agency Name and Packaging Type/Transport Mode Selection

Regulatory Information: Risk Phrases - Class.

GHS: Classification

**Training information** Follow training instructions when handling this material.

Material name: ZOVIRAX OPHTHALMIC OINTMENT

SDS MALTA

# Disclaimer

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Material name: ZOVIRAX OPHTHALMIC OINTMENT

SDS MALTA 127132 Version #: 10 Revision date: 23-October-2014 Issue date: 23-October-2014